Plain-English translation of NCT06706401 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a new way to treat head and neck cancer using radiation therapy that targets only the affected side of your neck, combined with or without a medication called ATRA (), which is a form of vitamin A. The study aims to see whether this approach can help preserve your immune system better than standard treatment and potentially improve your chances of staying cancer-free.
Standard radiation therapy for head and neck cancer can affect the immune system in ways that may actually reduce the body's ability to fight remaining cancer cells. Researchers believe that using a more targeted radiation approach and adding this medication might protect your immune system while still treating the cancer effectively.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to one of four treatment groups: standard radiation alone, targeted radiation with the medication, standard radiation with the medication, or targeted radiation alone. Your treatment will involve 6 to 8 weeks of radiation therapy (some groups will also receive chemotherapy or another standard medication), plus regular follow-up visits. If you receive the medication, you'll take it for a few days before treatment starts and then in cycles for several months after treatment ends. You'll be monitored for at least 2 years to see how well the treatment works and how you're doing.
AI-generated summary from trial data · Jun 13, 2026 · Not medical advice
France